文献速递白血病造血干细胞移植与细胞治疗

伴有持久移植物抗白血病反应的患者中存在急性髓系白血病特异性细胞毒性抗体

AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses.
PubMed 文献 · Blood · 2017-10-23

研究从具有强效持久移植物抗白血病(GVL)反应的高危急性髓系白血病(AML)患者B细胞中分离单克隆抗体,发现部分供者来源抗体识别U5 snRNP200复合物,该复合物在正常细胞内而在AML细胞膜暴露,抗体可经Fc受体依赖方式诱导AML细胞死亡,并在小鼠模型中显著抑制肿瘤生长。

要点

  • 从高危AML伴持久GVL反应患者B细胞中分离出针对AML细胞表面抗原的单克隆抗体。
  • 部分供者来源抗体识别U5 snRNP200复合物,该复合物在正常细胞内而在AML细胞膜暴露。
  • U5 snRNP200复合物特异性抗体经Fc受体依赖方式诱导AML细胞死亡,小鼠模型中显著抑制肿瘤生长。

核心结论

  • 供者来源的识别U5 snRNP200复合物的AML特异性抗体可能参与抗肿瘤反应。

研究设计与样本

  • 从具有强效持久GVL反应的高危AML患者B细胞中分离单克隆抗体。
  • 在AML小鼠模型中进行抗体治疗实验。

主要发现

  • 部分供者来源抗体识别U5 snRNP200复合物,该复合物在正常细胞中位于细胞内,在AML中暴露于白血病原始细胞膜。
  • U5 snRNP200复合物特异性抗体在无细胞毒性白细胞或补体存在下,以Fc受体依赖方式诱导AML细胞死亡。
  • 在AML小鼠模型中,U5 snRNP200复合物特异性抗体治疗导致显著的肿瘤生长抑制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most patients with acute myeloid leukemia (AML) can only be cured when allogeneic hematopoietic stem-cell transplantation induces a graft-versus-leukemia immune response (GVL). Although the role of T cells and natural killer cells in tumor immunology has been established, less is known about the contribution of B cells. From B cells of high-risk patients with AML with potent and lasting GVL responses, we isolated monoclonal antibodies directed against antigens expressed on the cell surface of AML cells but not on normal hematopoietic and nonhematopoietic cells. A number of these donor-derived antibodies recognized the U5 snRNP200 complex, a component of the spliceosome that in normal cells is found in the cell. In AML however, the U5 snRNP200 complex is exposed on the cell membrane of leukemic blasts. U5 snRNP200 complex-specific antibodies induced death of AML cells in an Fc receptor-dependent way in the absence of cytotoxic leukocytes or complement. In an AML mouse model, treatment with U5 snRNP200 complex-specific antibodies led to significant tumor growth inhibition. Thus, donor-derived U5 snRNP200 complex-recognizing AML-specific antibodies may contribute to antitumor responses.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gillissen MA, Kedde M, Jong G, et al. AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses. Blood. 2017. PMID: 29061569. doi:10.1182/blood-2017-02-768762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。